Key result
Preoperative serum syndecan-1 ≥90 ng/mL predicted severe acute kidney injury after valvular heart surgery (AUC 0.714; 95% CI 0.575-0.853; p=0.009) and was associated with prolonged hospitalization.
Why the study?
Endothelial glycocalyx degradation is associated with inflammation and endothelial dysfunction that may contribute to acute kidney injury, but its association with AKI after valvular heart surgery required investigation.
Does high preoperative serum syndecan-1 predict severe acute kidney injury in patients undergoing valvular heart surgery?
Observational (n=250)
Does high preoperative serum syndecan-1 predict severe acute kidney injury in patients undergoing valvular heart surgery?
High preoperative serum syndecan-1 (≥90 ng/mL) is an independent predictor of severe acute kidney injury and prolonged hospitalization following valvular heart surgery.
May aid preoperative AKI risk stratification in valvular surgery; leaves open prospective validation before clinical adoption.
Degradation of endothelial glycocalyx (EG) is associated with inflammation and endothelial dysfunction, which may contribute to the development of acute kidney injury (AKI). We investigated the association between a marker of EG degradation and AKI after valvular heart surgery. Serum syndecan-1 concentrations were measured at induction of anesthesia and discontinuation of cardiopulmonary bypass in 250 patients. Severe AKI was defined as Kidney Disease: Improving Global Outcomes Criteria Stage 2 or 3. Severe AKI occurred in 13 patients (5%). Receiver operating characteristic analysis of preoperative syndecan-1 to predict severe AKI showed area under curve of 0.714 (95% confidence interval (CI), 0.575–0.853; p = 0.009). The optimal cut-off value was 90 ng/mL, with a sensitivity of 61.5% and specificity of 78.5%. In multivariable analysis, both preoperative syndecan-1 ≥ 90 ng/mL and Cleveland Clinic Foundation score independently predicted severe AKI. Severe tricuspid regurgitation was more frequent (42.4% vs. 17.8%, p < 0.001), and baseline right ventricular systolic pressure (41 (33–51) mmHg vs. 33 (27–43) mmHg, p = 0.001) and TNF-α (1.85 (1.37–2.43) pg/mL vs. 1.45 (1.14–1.92) pg/mL, p <0.001) were higher in patients with high preoperative syndecan-1. Patients with high preoperative syndecan-1 had longer hospital stay (16 (12–24) days vs. 13 (11–17) days, p = 0.001). In conclusion, a high preoperative syndecan-1 concentration greater than 90 ng/mL was able to predict severe AKI after valvular heart surgery and was associated with prolonged hospitalization.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2020) conducted an observational in Valvular heart surgery (n=250). High preoperative serum syndecan-1 (≥ 90 ng/mL) vs. Low preoperative serum syndecan-1 (< 90 ng/mL) was evaluated on Severe acute kidney injury (KDIGO Stage 2 or 3) (AUC 0.714, 95% CI 0.575-0.853, p=0.009). Preoperative serum syndecan-1 ≥90 ng/mL predicted severe acute kidney injury after valvular heart surgery (AUC 0.714; 95% CI 0.575-0.853; p=0.009) and was associated with prolonged hospitalization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: